Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

← catalyst calendar

NCT05518123 · results posted

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
962actual
Sites
111
Countries
Australia, Austria, Belgium +11

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-11-07actualWhen the study began enrolling
Primary completion2025-03-31actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-07-08actualThe whole study's end, after follow-up
First posted2022-08-26actualWhen this record first appeared on the registry
Results posted2026-05-22actualWhen the sponsor posted results to the registry
Record updated2026-05-22actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Migraine

Interventions

  • Drug: Rimegepant
  • Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF
Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
measured Observation phase (28 days prior to randomization), DBT phase (through Month 3 [Week 1 to 12])

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2024-09-04 · 818 KB · Prot_000.pdf
Statistical Analysis Planposted 2025-05-20 · 773 KB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed